These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1253953)

  • 1. [Bioavailability of a delayed-action form of a coronary-dilator agent].
    Sestini G; Zagaria F
    Farmaco Prat; 1976 Feb; 31(2):102-10. PubMed ID: 1253953
    [No Abstract]   [Full Text] [Related]  

  • 2. [Potentials for carbocromen uptake via the skin].
    Bake MIa; Baumane ME
    Gig Tr Prof Zabol; 1983 Dec; (12):42-3. PubMed ID: 6667869
    [No Abstract]   [Full Text] [Related]  

  • 3. [Influence of carbocromen and of other coronary dilator agents on the blood flow of a myocardial ischemic area].
    Faucon G; Ollagnier M; de Claviere M; Kofman J; Evreux JC
    Therapie; 1975; 30(2):185-95. PubMed ID: 1162641
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficiency of carbocromen in coronary heart disease--an application problem?].
    Rupprecht E
    ZFA (Stuttgart); 1977 Jun; 53(17):1010-4. PubMed ID: 329600
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of carbocromene on myocardial oxygen consumption in isolated dog hearts.
    Fiedler VB; Scholtholt J
    J Pharmacol Exp Ther; 1981 May; 217(2):306-13. PubMed ID: 7229974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of coronary vasodilation on the healthy and ischemic myocardium in the dog].
    Tato F; Garnier M; Berdeaux A; Giudicelli JF
    Arch Farmacol Toxicol; 1978 Dec; 4(3):319-30. PubMed ID: 218502
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antilipemic and coronary-active treatment of arteriosclerosis: clinical experience].
    Poggio R; Velle G
    Clin Ter; 1978 Jul; 86(2):129-35. PubMed ID: 743855
    [No Abstract]   [Full Text] [Related]  

  • 8. [On coronary dilator action of athamantin].
    Khadzhaĭ IaI; Kuznetsova VF
    Farm Zh; 1965; 20(4):47-51. PubMed ID: 5877459
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.
    Brockmeier D; von Hattingberg HM
    Arzneimittelforschung; 1982; 32(3):248-51. PubMed ID: 6896279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bioavailability of potassium chloride from delayed-action preparations].
    Holzgreve H; Stephan R
    Med Welt; 1978 Oct; 29(43):1702-6. PubMed ID: 713790
    [No Abstract]   [Full Text] [Related]  

  • 11. [Differences in the bioavailability of delayed action and standard preparations of calcium antagonists].
    Blume H
    Internist (Berl); 1994 Aug; 35(8):782-3. PubMed ID: 7960558
    [No Abstract]   [Full Text] [Related]  

  • 12. [Influence of food on the bioavailability of theophylline in a delayed-release dosage form (Dilatrane AP)].
    Flouvat B; Delhotal-Landes B; Boutin-Pannetier MS
    Therapie; 1986; 41(2):144-5. PubMed ID: 3726788
    [No Abstract]   [Full Text] [Related]  

  • 13. [Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form].
    Blanc M; Cales P; Grasset D; Ravaud A; Meskens C; Cotonat J; Pascal JP
    Therapie; 1987; 42(2):187-91. PubMed ID: 3616995
    [No Abstract]   [Full Text] [Related]  

  • 14. [Site of action of the coronary drug carbocromen].
    Alfes H; Schraven E; Möllmann H; Ostrowski J; Bigalke G; Nitz RE
    Fortschr Med; 1973 Jul; 91(19):837-43. PubMed ID: 4198875
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bioavailability of indomethacin. Study of a delayed-action preparation].
    Vignon E; Chapuy MC
    Rev Rhum Mal Osteoartic; 1979; 46(7-9):505-8. PubMed ID: 583080
    [No Abstract]   [Full Text] [Related]  

  • 16. Papaverine bioavailability in delayed absorption formulations.
    Melloni GF; Melloni R
    Boll Soc Ital Biol Sper; 1981 Jul; 57(14):1489-95. PubMed ID: 7295412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological availability of potassium from a sustained release preparation].
    Müller A; Thoma M; Renker H
    Schweiz Med Wochenschr; 1976 Jan; 106(1):27-30. PubMed ID: 1251146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceutical evaluation of ferrous salts in form of oral long-acting tablets.
    Krzyśko K; Bokowski W; Wichliński LM
    Pol J Pharmacol Pharm; 1984; 36(1):73-7. PubMed ID: 6462964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Release and bioavailability of a cimetidine retard formula].
    Hillebrand F
    Wien Med Wochenschr; 1985 Apr; 135(8):191-6. PubMed ID: 4013349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The bioavailability of Ce-Ferro forte].
    Heinrich HC; Gabbe EE
    Med Klin; 1979 Aug; 74(32-33):1196-8. PubMed ID: 470799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.